Business Context and Reporting Period
This Form 8-K filing by Atricure, Inc. is dated September 3, 2013. The report discloses changes to the Board of Directors, specifically the appointment of a new director and the announced retirement of a founding director.
Key Financial Metrics
The filing does not provide financial metrics (revenue, profit, cash flow, margins, debt, or liquidity) for Atricure, Inc. for the current period. The document references financial data for Spectranetics Corporation, a separate entity where the new appointee serves as CEO, noting Spectranetics reported $140.3 million in revenue in 2012.
Material Changes
- Appointment of Director: Scott Drake was appointed to the Board of Directors effective September 3, 2013, serving until the next Annual Meeting of Stockholders. He is deemed an independent director.
- Retirement Announcement: Donald C. Harrison, MD, a founder of Atricure, plans to retire from the Board at the 2013 Annual Meeting in May 2014 following nearly 20 years of service.
Management Commentary and Risks
Management highlights Mr. Drake's extensive background in the medical device and healthcare sectors, including his role as President and CEO of Spectranetics Corporation and previous leadership roles at DaVita, Inc. and Covidien, Plc. The filing states there are no undisclosed transactions or arrangements between the Company and Mr. Drake. Compensation for his director service will align with existing policies for non-employee directors.
Investor Verification Checklist
- Verify the independence status of Scott Drake under NASDAQ listing standards.
- Review the Company's proxy statement filed on April 12, 2013, for details on director compensation policies.
- Confirm the timeline for the transition of duties following Dr. Harrison's planned retirement in May 2014.
- Check for any subsequent filings regarding the formal election of Mr. Drake at the next Annual Meeting.